Ascletis Advances Oral Amylin Agonist with Promising Early Data
Event summary
- Ascletis Pharma selected ASC36, an oral amylin receptor peptide agonist, for clinical development, utilizing its proprietary POTENT technology.
- ASC36 demonstrated up to 13.2% body weight reduction and significant food intake reduction in non-human primate (NHP) studies with once-daily dosing.
- In a rat model, ASC36 showed superior weight loss compared to eloralintide and petrelintide.
- Ascletis anticipates submitting an Investigational New Drug Application (IND) to the FDA in Q2 2026.
- ASC36's oral bioavailability of 6-8% and long elimination half-life (116-167 hours) suggest potential for lower doses and scalability advantages.
The big picture
The obesity treatment market is experiencing rapid innovation, with oral peptide agonists representing a significant advancement over injectable options. Ascletis' POTENT technology, if validated in clinical trials, could provide a competitive edge by enabling convenient oral delivery and potentially reducing manufacturing costs. The success of ASC36 will hinge on demonstrating superior efficacy and safety compared to existing and emerging therapies in a crowded market.
What we're watching
- Clinical Trial Design
- The clinical trial design for ASC36 will be critical in demonstrating efficacy and safety compared to existing therapies, particularly given the relatively low oral bioavailability.
- Regulatory Pathway
- The FDA's response to the IND submission and subsequent review process will dictate the timeline for potential market entry and influence investor sentiment.
- Competitive Landscape
- Ascletis will need to clearly differentiate ASC36 from emerging oral GLP-1R agonists and other amylin-targeting therapies to secure market share.
Related topics